T2 Biosystms Financials
TTOO Stock | USD 0.58 0.01 1.75% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 0.43 | 0.4486 |
|
|
The essential information of the day-to-day investment outlook for T2 Biosystms includes many different criteria found on its balance sheet. An individual investor should monitor T2 Biosystms' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in T2 Biosystms.
Net Income |
|
TTOO | Select Account or Indicator |
T2 Biosystms Stock Summary
T2 Biosystms competes with Genetic Technologies, Intelligent Bio, BioAffinity Technologies,, Thermo Fisher, and Illumina. T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts. T2 Biosystems operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 182 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US89853L1044 |
CUSIP | 89853L104 89853L203 89853L302 |
Location | Massachusetts; U.S.A |
Business Address | 101 Hartwell Avenue, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.t2biosystems.com |
Phone | 781 761 4646 |
Currency | USD - US Dollar |
T2 Biosystms Key Financial Ratios
Return On Equity | -6.22 | ||||
Operating Margin | (4.91) % | ||||
Price To Sales | 1.68 X | ||||
Revenue | 7.19 M | ||||
Gross Profit | (24.77 M) |
T2 Biosystms Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 28.5M | 79.1M | 60.5M | 34.4M | 34.8M | 43.7M | |
Other Current Liab | 13.6M | 6.4M | 7.2M | 6.0M | 9.9M | 6.8M | |
Other Liab | 46K | 4.8M | 4.6M | 4.9M | 5.6M | 5.9M | |
Net Debt | 33.7M | 39.0M | 34.9M | 48.9M | 33.8M | 35.5M | |
Retained Earnings | (376.2M) | (423.0M) | (472.2M) | (534.5M) | (584.3M) | (555.1M) | |
Accounts Payable | 3.8M | 2.1M | 2.8M | 1.3M | 1.5M | 1.6M | |
Cash | 11.0M | 16.8M | 22.2M | 10.3M | 15.7M | 28.6M | |
Other Current Assets | 1.4M | 2.7M | 3.1M | 2.6M | 3.3M | 1.7M | |
Total Liab | 62.5M | 70.4M | 73.4M | 74.4M | 62.8M | 50.8M | |
Total Current Assets | 18.9M | 53.6M | 44.4M | 19.4M | 25.2M | 35.3M | |
Short Term Debt | 42.9M | 1.2M | 1.2M | 2.7M | 44.5M | 46.7M | |
Common Stock | 49K | 147K | 166K | 8K | 4K | 3.8K | |
Net Tangible Assets | (32.1M) | 8.7M | (12.9M) | (40.0M) | (36.0M) | (34.2M) | |
Net Receivables | 2.8M | 5.1M | 5.1M | 2.2M | 1.4M | 2.2M | |
Capital Surpluse | 267.4M | 328.5M | 342.1M | 431.5M | 496.3M | 308.8M | |
Inventory | 3.6M | 3.6M | 3.9M | 4.3M | 4.8M | 2.9M | |
Short Long Term Debt | 40.7M | 42.4M | 42.9M | 41.3M | 47.5M | 27.2M |
T2 Biosystms Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 7.3M | 5.5M | 6.6M | 6.1M | 5.3M | 4.9M | |
Total Revenue | 8.3M | 18.1M | 28.1M | 22.3M | 7.2M | 9.8M | |
Gross Profit | (8.4M) | (3.2M) | 7.4M | 1.2M | (8.2M) | (7.8M) | |
Operating Income | (52.1M) | (41.4M) | (43.0M) | (55.5M) | (49.7M) | (52.1M) | |
Ebit | (51.8M) | (41.6M) | (43.7M) | (57.5M) | (44.7M) | (47.0M) | |
Research Development | 16.3M | 16.9M | 21.8M | 25.9M | 14.2M | 21.0M | |
Ebitda | (51.7M) | (38.5M) | (41.1M) | (55.2M) | (43.9M) | (46.1M) | |
Cost Of Revenue | 16.8M | 21.3M | 20.7M | 21.1M | 15.4M | 17.9M | |
Income Before Tax | (59.0M) | (46.8M) | (49.2M) | (62.3M) | (50.1M) | (52.6M) | |
Net Income | (63.1M) | (49.2M) | (53.5M) | (63.4M) | (50.1M) | (52.6M) | |
Income Tax Expense | 4.1M | 2.4M | 4.3M | 1.1M | 691.1K | 656.6K | |
Interest Income | 7.3M | 14K | 112K | 8K | 7.2K | 6.8K | |
Net Interest Income | (7.3M) | (5.5M) | (6.5M) | (6.1M) | (5.7M) | (6.0M) |
T2 Biosystms Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (39.8M) | 6.1M | 6.5M | (11.9M) | 4.4M | 4.6M | |
Free Cash Flow | (46.1M) | (44.0M) | (39.3M) | (51.0M) | (48.3M) | (50.7M) | |
Depreciation | 3.6M | 3.2M | 2.5M | 2.3M | 859K | 816.1K | |
Other Non Cash Items | 2.4M | 3.3M | 3.9M | 3.1M | 773K | 734.4K | |
Capital Expenditures | 761K | 804K | 460K | 339K | 192K | 182.4K | |
Net Income | (59.0M) | (46.8M) | (49.2M) | (62.0M) | (50.1M) | (52.6M) | |
End Period Cash Flow | 11.2M | 17.3M | 23.8M | 11.9M | 16.2M | 28.9M | |
Change To Inventory | (914K) | 441K | (1.9M) | (949K) | (744K) | (781.2K) | |
Change Receivables | (140K) | (1.3M) | (1.0M) | (2.3M) | (2.0M) | (1.9M) | |
Change To Netincome | 12.5M | 8.1M | 7.0M | 10M | 11.5M | 8.1M | |
Investments | (761K) | (35.5M) | 25.3M | 9.7M | (202K) | (212.1K) |
TTOO Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining T2 Biosystms's current stock value. Our valuation model uses many indicators to compare T2 Biosystms value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across T2 Biosystms competition to find correlations between indicators driving T2 Biosystms's intrinsic value. More Info.T2 Biosystms is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, T2 Biosystms' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the T2 Biosystms' earnings, one of the primary drivers of an investment's value.T2 Biosystms Systematic Risk
T2 Biosystms' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. T2 Biosystms volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on T2 Biosystms correlated with the market. If Beta is less than 0 T2 Biosystms generally moves in the opposite direction as compared to the market. If T2 Biosystms Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one T2 Biosystms is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of T2 Biosystms is generally in the same direction as the market. If Beta > 1 T2 Biosystms moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in T2 Biosystms Stock are looking for potential investment opportunities by analyzing not only static indicators but also various T2 Biosystms' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of T2 Biosystms growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
T2 Biosystms December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of T2 Biosystms help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of T2 Biosystms. We use our internally-developed statistical techniques to arrive at the intrinsic value of T2 Biosystms based on widely used predictive technical indicators. In general, we focus on analyzing TTOO Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build T2 Biosystms's daily price indicators and compare them against related drivers.
Information Ratio | (0.42) | |||
Maximum Drawdown | 26.0 | |||
Value At Risk | (12.50) | |||
Potential Upside | 6.19 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.03) | Revenue Per Share 0.999 | Quarterly Revenue Growth (0.01) | Return On Assets (0.90) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.